Thyroid Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, Companies by DelveInsight

DelveInsight's, "Thyroid Cancer Pipeline Insight" report provides comprehensive insights about 50+ companies and 51+ pipeline drugs in Thyroid Cancer pipeline landscape. It covers the Thyroid Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Thyroid Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight's comprehensive Thyroid Cancer Pipeline Report to explore emerging therapies, key Thyroid Cancer Companies, and future Thyroid Cancer treatment landscapes @ Thyroid Cancer Pipeline Outlook Report [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Thyroid Cancer Pipeline Report

* In February 2025:- Bayer:- This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
* In February 2025:- Turning Point Therapeutics, Inc.:- Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.
* In February 2025:- Sanofi:- The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
* In February 2025:- Loxo Oncology Inc.:- The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that cannot be removed by surgery or has spread to other parts of the body. Participants who are assigned to the standard treatment and discontinue due to progressive disease have the option to potentially crossover to selpercatinib.
* In February 2025:- Eli Lilly and Company;- A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation.
* DelveInsight's Thyroid Cancer pipeline report depicts a robust space with 50+ active players working to develop 51+ pipeline therapies for Thyroid Cancer treatment.
* The leading Thyroid Cancer Companies such as AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories , and others.
* Promising Thyroid Cancer Therapies such as Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.

Discover how the Thyroid Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Thyroid Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Thyroid Cancer Clinical Trials and Studies [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Thyroid Cancer Emerging Drugs

* rhTSH: Suzhou Zelgen Biopharmaceuticals

Recombinant human TSH (rhTSH) was developed to provide TSH stimulation without the requirement for THST withdrawal and the resultant metabolic disturbance, and without the drawbacks associated with the use of bovine TSH. The drug is currently being evaluated under Phase III clinical trial for the treatment of patients with thyroid cancer.

* Nivolumab: Bristol-Myers Squibb

Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with thyroid cancer.

* RX208: Suzhou NeuPharma

RX208 is a potential "best-in-class" BRAF V600E inhibitor with a proprietary novel chemical structure that is different from other marketed BRAF inhibitors. It exhibited high bioavailability and excellent anti-tumor efficacy in preclinical studies. Early clinical data demonstrated preliminary efficacy and good safety and tolerability in patients with cancer, warranting further clinical development. The drug is currently being evaluated under Phase I/II clinical trial for the treatment of patients with thyroid cancer.

* AIC100: AffyImmune Therapeutics

AffyImmune's lead product, AIC100, is an affinity-tuned, ICAM-1 targeted, third generation CAR T cell therapy. AIC100's CAR has an affinity to ICAM-1 similar to the affinity between naturally-occurring T cells and their targets, which is much lower than most CARs used to date and reduces on-target off-tumor toxicities. AIC100 also expresses SSTR2 for real-time monitoring of CAR T cell distribution and activity. Preclinical studies demonstrate that AIC100 induces robust and enduring tumor eradication without toxicity-related relapse or fatality in various solid tumor models. Studies also suggest the potential for combination with anti-PD-1 therapies. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Thyroid Cancer.

The Thyroid Cancer pipeline report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Thyroid Cancer with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Thyroid Cancer Treatment.
* Thyroid Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Thyroid Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Thyroid Cancer market.

Get a detailed analysis of the latest innovations in the Thyroid Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Thyroid Cancer Unmet Needs [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Thyroid Cancer Companies

AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.

Thyroid Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

* Intravenous
* Subcutaneous
* Oral
* Intramuscular

Thyroid Cancer Products have been categorized under various Molecule types such as

* Monoclonal antibody
* Small molecule
* Peptide

Download DelveInsight's latest report to gain strategic insights into upcoming Thyroid Cancer Therapies and key Thyroid Cancer Developments @ Thyroid Cancer Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Thyroid Cancer Pipeline Report

* Coverage- Global
* Thyroid Cancer Companies- AffyImmune Therapeutics, Suzhou Zelgen Biopharmaceuticals, Bristol-Myers Squibb, Suzhou NeuPharma, AstraZeneca, Verastem Oncology, Thryv Therapeutics, Molecular Targeting Technologies, Chimerix, Codiak BioSciences, LeadArtis, Tyra Biosciences, Roche, Sichuan Kelun-Biotech Biopharmaceutical, Advenchen Laboratories, and others.
* Thyroid Cancer Therapies- Selpercatinib, Cabozantinib, Vandetanib, E7080 Capsule, Lenvatinib (DTC Cohort), Irofulven + capecitabine, XL184, AL2846 Capsule, and others.
* Thyroid Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Thyroid Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Thyroid Cancer drug development? Find out in DelveInsight's exclusive Thyroid Cancer Pipeline Report-access it now! @ Thyroid Cancer Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/thyroid-cancer-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

* Introduction
* Executive Summary
* Thyroid Cancer: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Thyroid Cancer- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* rhTSH: Suzhou Zelgen Biopharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Nivolumab: Bristol-Myers Squibb
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* AIC100:Affyimmune Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Thyroid Cancer Key Companies
* Thyroid Cancer Key Products
* Thyroid Cancer- Unmet Needs
* Thyroid Cancer- Market Drivers and Barriers
* Thyroid Cancer- Future Perspectives and Conclusion
* Thyroid Cancer Analyst Views
* Thyroid Cancer Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=thyroid-cancer-clinical-trials-and-studies-ema-pdma-fda-approvals-mechanism-of-action-roa-nda-ind-companies-by-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/car-t-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com